Generic placeholder image

Current Drug Safety

Author(s): Chander Singh, Komal Rao, Nikita Yadav, Yogesh Vashist, Palak Chugh, Nidhi Bansal and Neha Minocha*

DOI: 10.2174/1574886317666220902100511

DownloadDownload PDF Flyer Cite As
Current Cannabidiol Safety: A Review

Page: [465 - 473] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: Marijuana, also known as cannabis, is the second most widely used illegal psychoactive substance smoked worldwide after tobacco, mainly due to the psychoactive effects induced by D-9-tetrahydrocannabinol (9-THC). Cannabidiol (CBD) is extracted from cannabis and may be used as an anti-inflammatory agent. Some patents on cannabidiol are discussed in this review. The cannabinoid is a non-psychoactive isomer of the more infamous tetrahydrocannabinol (THC); and is available in several administration modes, most known as CBD oil.

Objectives: This study aims to provide an enhanced review of cannabidiol properties used in treating inflammation. This review also emphasises the current safety profile of cannabidiol.

Methods: Cannabis is also called Marijuana. It is the second most commonly used illegal psychoactive substance in the universe after tobacco. D-9-tetrahydrocannabinol (9-THC) present in cannabis produces psychoactive effects. Cannabidiol (CBD) extracted from cannabis is used for antiinflammatory purposes. Cannabis smoking causes various types of cancer, such as lung, tongue, and jaw. The current review took literature from Google Scholar, PubMed, and Google Patents. Many clinical investigations are included in this review.

Result: After analysing the literature on cannabis, it has been suggested that although cannabis is banned in some countries, it may be included in the treatment and mitigation of some diseases and symptoms like pain management, epilepsy, cancer, and anxiety disorder. Mild side effects were frequently observed in cannabis medications, which included infertility in females, liver damage, etc.

Conclusion: Cannabis contains chemical compounds such as the cannabinoids delta-9- tetrahydrocannabinol (THC), a psychoactive substance, and non-psychoactive cannabidiol (CBD). Cannabidiol has been confirmed as an efficient treatment of epilepsy in several clinical trials, with one pure CBD product named Epidiolex. It is also used in treating anxiety and acne, as a pain reliever, and has anti-inflammatory properties.

Keywords: Cannabidiol, CBD, Cannabis, Marijuana, Safety, D-9-tetrahydrocannabinol (9-THC)

Graphical Abstract

[1]
Omare M, Kibet J, Cherutoi J, Kengara F. A review of the current trends on the use of Cannabis sativa for recreational, medicinal applications, and its toxicological health impacts. Authorea 2020.
[http://dx.doi.org/10.22541/au.159318524.43742889]
[2]
Archie SR, Cucullo L. Harmful effects of smoking cannabis: a cerebrovascular and neurological perspective. Front Pharmacol 2019; 10: 1481.
[http://dx.doi.org/10.3389/fphar.2019.01481] [PMID: 31920665]
[3]
Borgan F, Beck K, Butler E, et al. The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. Psychopharmacology 2019; 236(11): 3257-70.
[http://dx.doi.org/10.1007/s00213-019-05283-3] [PMID: 31165913]
[4]
Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Accad Sci 2000.
[http://dx.doi.org/10.1073/pnas.160105897]
[5]
WHO. WHO Expert committee on drug dependence: fortieth report. 2018. Available from: https://apps.who.int/iris/handle/10665/279948
[6]
All studies reported ADE N. Symptoms of Cannabis Withdrawal. Lancet 2018; 3: e341-50.
[7]
Tyndall JA, Gerona R, De Portu G, et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol 2015; 53(10): 950-6.
[http://dx.doi.org/10.3109/15563650.2015.1100306] [PMID: 26555732]
[8]
Kim NP, Aditya A, Kang HJ, Park HD. Unique approach of a telemedicine system for CBD-infused foods. Processes 2021; 9(6): 936.
[http://dx.doi.org/10.3390/pr9060936]
[9]
Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem 2016; 62(12): 1579-92.
[http://dx.doi.org/10.1373/clinchem.2016.263475] [PMID: 27899456]
[10]
Solowij N, Broyd SJ, van Hell HH, Hazekamp A. A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol 2014; 15(1): 58.
[http://dx.doi.org/10.1186/2050-6511-15-58] [PMID: 25319497]
[11]
Echeverria VM, Todeschini AB, Stoicea N, Fiorda DJ, Weaver T, Bergese SD. Perioperative care of cannabis users: A comprehensive review of pharmacological and anesthetic considerations. J Clin Anesth 2019; 57: 41-9.
[http://dx.doi.org/10.1016/j.jclinane.2019.03.011] [PMID: 30852326]
[12]
Johansson E, Norén K, Sjövall J, Halldin MM. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 1989; 3(1): 35-8.
[http://dx.doi.org/10.1002/bmc.1130030109] [PMID: 2539872]
[13]
Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018; 84(11): 2477-82.
[http://dx.doi.org/10.1111/bcp.13710] [PMID: 30001569]
[14]
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42(4): 327-60.
[http://dx.doi.org/10.2165/00003088-200342040-00003] [PMID: 12648025]
[15]
Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. Single-dose kinetics of deuterium labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom 1986; 13(2): 77-83.
[http://dx.doi.org/10.1002/bms.1200130206] [PMID: 2937482]
[16]
Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007; 4(8): 1770-804.
[http://dx.doi.org/10.1002/cbdv.200790152] [PMID: 17712819]
[17]
Martin JH, Schneider J, Lucas CJ, Galettis P. Exogenous cannabinoid efficacy: merely a pharmacokinetic interaction? Clin Pharmacokinet 2018; 57(5): 539-45.
[http://dx.doi.org/10.1007/s40262-017-0599-0] [PMID: 28921125]
[18]
Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol 2008; 32(7): 470-7.
[http://dx.doi.org/10.1093/jat/32.7.470] [PMID: 18713514]
[19]
Byars T, Theisen E, Bolton DL. Using cannabis to treat cancer related pain. Seminars in Oncology Nursing In: Elsevier Amsterdam 2019; 35(3): 300-9.
[http://dx.doi.org/10.1016/j.soncn.2019.04.012]
[20]
Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav 2017; 70: 313-8.
[http://dx.doi.org/10.1016/j.yebeh.2016.11.016] [PMID: 28087250]
[21]
Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillespie H, Hollister L. Interactions ofΔ 11-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia 1981; 37(10): 1090-2.
[http://dx.doi.org/10.1007/BF02085029] [PMID: 6273208]
[22]
Eichler M, Spinedi L, Unfer GS, et al. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med 2012; 78(7): 686-91.
[http://dx.doi.org/10.1055/s-0031-1298334] [PMID: 22411724]
[23]
Dinis RJ. Metabolomics of Δ9-tetrahydrocannabinol: Implications in toxicity. Drug Metab Rev 2016; 48(1): 80-7.
[http://dx.doi.org/10.3109/03602532.2015.1137307] [PMID: 26828228]
[24]
Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, Δ 9-tetrahydrocannibinol, cannabidiol and cannabinol. Cannabinoids 2005; pp. 657-90.
[http://dx.doi.org/10.1007/3-540-26573-2_23]
[25]
Challapalli PV, Stinchcomb AL. In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int J Pharm 2002; 241(2): 329-39.
[http://dx.doi.org/10.1016/S0378-5173(02)00262-4] [PMID: 12100860]
[26]
Lodzki M, Godin B, Rakou L, Mechoulam R, Gallily R, Touitou E. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release 2003; 93(3): 377-87.
[http://dx.doi.org/10.1016/j.jconrel.2003.09.001] [PMID: 14644587]
[27]
Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR. Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol 2004; 56(3): 291-7.
[http://dx.doi.org/10.1211/0022357022791] [PMID: 15025853]
[28]
Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy related neuroprotection. Epilepsy Behav 2017; 70(Pt B): 319-27.
[http://dx.doi.org/10.1016/j.yebeh.2016.11.006]
[29]
Schaefer N, Kettner M, Laschke MW, et al. Distribution of synthetic cannabinoids JWH-210, RCS-4 and Δ 9-Tetrahydrocannabinol after intravenous administration to pigs. Curr Neuropharmacol 2017; 15(5): 713-23.
[http://dx.doi.org/10.2174/1570159X15666161111114214] [PMID: 27834143]
[30]
Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980; 215(1): 35-44.
[PMID: 6256518]
[31]
Lucas CJ, Galettis P, Song S, et al. Cannabinoid disposition after human intraperitoneal use: An insight into intraperitoneal pharmacokinetic properties in metastatic cancer. Clin Ther 2018; 40(9): 1442-7.
[http://dx.doi.org/10.1016/j.clinthera.2017.12.008] [PMID: 29317112]
[32]
Zendulka O, Dovrtělová G, Nosková K, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 2016; 17(3): 206-26.
[http://dx.doi.org/10.2174/1389200217666151210142051] [PMID: 26651971]
[33]
Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: Whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 2011; 57(10): 1406-14.
[http://dx.doi.org/10.1373/clinchem.2011.171777] [PMID: 21836075]
[34]
Lemberger L, Crabtree RE, Rowe HM. 11-hydroxy- 9 -tetrahydrocannabinol: Pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 1972; 177(4043): 62-4.
[http://dx.doi.org/10.1126/science.177.4043.62] [PMID: 5041775]
[35]
Perez RM, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med 1982; 307(13): 819-20.
[http://dx.doi.org/10.1056/NEJM198209233071311] [PMID: 6287261]
[36]
Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 1991; 40(3): 701-8.
[http://dx.doi.org/10.1016/0091-3057(91)90386-G] [PMID: 1839644]
[37]
Heuberger JA, Guan Z, Oyetayo OO, et al. Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short and long term pharmacokinetics. Clin Pharmacokinet 2015; 54(2): 209-19.
[http://dx.doi.org/10.1007/s40262-014-0195-5] [PMID: 25316574]
[38]
Arellano AL, Papaseit E, Romaguera A, Torrens M, Farré M. Neuropsychiatric and general interactions of natural and synthetic cannabinoids with drugs of abuse and medicines. CNS & Neurol Disord Drug Targets 2017; 16(5): 554-66.
[http://dx.doi.org/10.2174/1871527316666170413104516]
[39]
Lukas SE, Orozco S. Ethanol increases plasma Δ(9)-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers. Drug Alcohol Depend 2001; 64(2): 143-9.
[http://dx.doi.org/10.1016/S0376-8716(01)00118-1] [PMID: 11543984]
[40]
Andréasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand 1989; 79(5): 505-10.
[http://dx.doi.org/10.1111/j.1600-0447.1989.tb10296.x] [PMID: 2787581]
[41]
Schoeler T, Monk A, Sami MB, et al. Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry 2016; 3(3): 215-25.
[http://dx.doi.org/10.1016/S2215-0366(15)00363-6] [PMID: 26777297]
[42]
Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol 2014; 113(1): 187-90.
[http://dx.doi.org/10.1016/j.amjcard.2013.09.042] [PMID: 24176069]
[43]
D’Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004; 29(8): 1558-72.
[http://dx.doi.org/10.1038/sj.npp.1300496] [PMID: 15173844]
[44]
Karschner EL, Darwin WD, McMahon RP, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 2011; 89(3): 400-7.
[http://dx.doi.org/10.1038/clpt.2010.318] [PMID: 21289620]
[45]
Dumont GJ, Kramers C, Sweep FC, et al. Cannabis coadministration potentiates the effects of “ecstasy” on heart rate and temperature in humans. Clin Pharmacol Ther 2009; 86(2): 160-6.
[http://dx.doi.org/10.1038/clpt.2009.62] [PMID: 19440186]
[46]
Benowitz NL, Jones RT. Prolonged delta-9-tetrahydrocannabinol ingestion. Effects of sympathomimetic amines and autonomic blockades. Clin Pharmacol Ther 1977; 21(3): 336-42.
[http://dx.doi.org/10.1002/cpt1977213336] [PMID: 837652]
[47]
Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD. Marijuana and cocaine interactions in humans: Cardiovascular consequences. Pharmacol Biochem Behav 1987; 28(4): 459-64.
[http://dx.doi.org/10.1016/0091-3057(87)90506-5] [PMID: 2829241]
[48]
Russo E, Guy GW. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66(2): 234-46.
[http://dx.doi.org/10.1016/j.mehy.2005.08.026] [PMID: 16209908]
[49]
Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 2015; 45(15): 3181-9.
[http://dx.doi.org/10.1017/S0033291715001178] [PMID: 26213314]
[50]
Lopez QC, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey On Alcohol And Related Conditions (NESARC). Drug Alcohol Depend 2011; 115(1-2): 120-30.
[http://dx.doi.org/10.1016/j.drugalcdep.2010.11.004] [PMID: 21145178]
[51]
John J. Everything you need to know about CBD oil. Medical News Today. 2020. Available from: https://www.medicalnewstoday.com/articles/317221
[52]
Li H, Kong W, Chambers CR, et al. The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice. Cell Immunol 2018; 329: 1-9.
[http://dx.doi.org/10.1016/j.cellimm.2018.02.016] [PMID: 29784129]
[53]
Morgan CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013; 38(9): 2433-6.
[http://dx.doi.org/10.1016/j.addbeh.2013.03.011] [PMID: 23685330]
[54]
Hindocha C, Freeman TP, Grabski M, et al. Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal. Addiction 2018; 113(9): 1696-705.
[http://dx.doi.org/10.1111/add.14243] [PMID: 29714034]
[55]
Hurd YL, Yoon M, Manini AF, et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 2015; 12(4): 807-15.
[http://dx.doi.org/10.1007/s13311-015-0373-7] [PMID: 26269227]
[56]
FDA Approves New Indication for Drug containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease. 2020. Available from: https://www.fda.gov/media/112565/download
[57]
Epidiolex. Medical News Today. Available from: https://www.medicalnewstoday.com/articles/epidiolex
[58]
Zieba J, Sinclair D, Sebree T, et al. Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism. Pharmacol Biochem Behav 2019; 181: 93-100.
[http://dx.doi.org/10.1016/j.pbb.2019.05.002] [PMID: 31063743]
[59]
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 2015; 12(4): 825-36.
[http://dx.doi.org/10.1007/s13311-015-0387-1] [PMID: 26341731]
[60]
Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest 2014; 124(9): 3713-24.
[http://dx.doi.org/10.1172/JCI64628] [PMID: 25061872]
[61]
FDA Regulations of Cannabis and Cannabis Derived Products, Including Cannabidiol (CBD). 2020. Retrieved from: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.
[62]
Naik S, Kolikonda M, Prabhu A, Lippmann S. Marijuana on the brain- A concern. Innov Clin Neurosci 2018; 15(1-2): 12.
[PMID: 30023136]
[63]
Hoffmann DB, Brunnemann KD, Gori GB, Wynder EL. On the carcinogenicity of marijuana smoke. In: Recent Advances in Phytochemistry. Springer 1975; pp. 63-81.
[http://dx.doi.org/10.1007/978-1-4684-0823-2_3]
[64]
Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988; 318(6): 347-51.
[http://dx.doi.org/10.1056/NEJM198802113180603] [PMID: 3340105]
[65]
Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008; 21(2): 494-502.
[http://dx.doi.org/10.1021/tx700275p] [PMID: 18062674]
[66]
Tashkin DP, Gliederer F, Rose J, et al. Tar, CO and delta 9THC delivery from the 1st and 2nd halves of a marijuana cigarette. Pharmacol Biochem Behav 1991; 40(3): 657-61.
[http://dx.doi.org/10.1016/0091-3057(91)90378-F] [PMID: 1666924]
[67]
Heinicke G, Clay R, DeCato TW. Six minute walk testing. ATS patient education series. American Thoracic Society. Am J Respir Crit Care Med 2021; 204: 9-10.
[68]
Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: A systematic review and meta-analysis. JAMA Netw Open 2019; 2(11): e1916318.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.16318] [PMID: 31774524]
[69]
Shakya G, Balasubramanian S, Rajagopalan R. Methanol extract of wheatgrass induces G1 cell cycle arrest in a p53-dependent manner and down regulates the expression of cyclin D1 in human laryngeal cancer cells-an in vitro and in silico approach. Pharmacognosy Magazine 2015; 11(42)
[70]
Sarah BMBS, Matire H, Brian C, et al. Cannabis use and cancer of the head and neck: Case control study. Otolaryngol Head Neck Surg 2008; 138: 374-80.
[71]
Singh H, Katz J, Saleh W, Cha S. Impact of cannabis on the port of entry-oral tissues: An overview. Int J Oral Dent Health 2019; 5: 098.
[72]
Versteeg PA, Slot DE, van der Velden U, van der Weijden GA. Effect of cannabis usage on the oral environment: A review. Int J Dent Hyg 2008; 6(4): 315-20.
[http://dx.doi.org/10.1111/j.1601-5037.2008.00301.x] [PMID: 19138182]
[73]
Darling MR, Arendorf TM. Effects of cannabis smoking on oral soft tissues. Community Dent Oral Epidemiol 1993; 21(2): 78-81.
[http://dx.doi.org/10.1111/j.1600-0528.1993.tb00725.x] [PMID: 8485974]
[74]
Schulz KM, Imfeld T, Imfeld C. Cannabis and caries-does regular cannabis use increase the risk of caries in cigarette smokers? Schweiz Monatsschr Zahnmed 2009; 119(6): 576-83.
[PMID: 20112637]
[75]
Pikkarainen PH, Baraona E, Jauhonen P, Seitz HK, Lieber CS. Contribution of oropharynx microflora and of lung microsomes to acetaldehyde in expired air after alcohol ingestion. J Lab Clin Med 1981; 97(5): 631-6.
[PMID: 7194361]
[76]
Di Cugno F, Perec CJ, Tocci AA. Salivary secretion and dental caries experience in drug addicts. Arch Oral Biol 1981; 26(5): 363-7.
[http://dx.doi.org/10.1016/0003-9969(81)90031-5] [PMID: 6947736]
[77]
Berl V. Xiac. New Age Nanotech LLC, Stabilized formulations ofcannabinoid compositions. Patent US20200138772A1, 2019.
[78]
Bradley MB. Cannabidiol (CBD) enriched alcohol. Patent US9539295B2, 2015.
[79]
Def LLC. Topical regional neuro-affective therapy with cannabinoids. Patent US10716766B2, 2016.
[80]
Michael JM, Joshua A, H, Greg W. Process for generating hemp oil with a high cannabidiol (CBD) content. Patent US10882808B2, 2015.
[81]
Heller M. Methodology and formulation for creating a powder of an encapsulated cannabis-based component embedded in a polymer matrix. Patent US20200054702A1, 2018.